Although immunotherapy has improved outcomes in many subsets of NSCLC, it is generally considered less effective in tumors harboring driver genomic alterations such as EGFR and ALK, further emphasizing the importance of molecularly targeted therapies in these settings. This evidence concerns the gene EGFR and non-small cell lung carcinoma.